Overview

the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

Gastrointestinal vascular malformation (GIVM), which is an important cause of acute or chronic gastrointestinal bleeding, currently lacks of effective treatment. The investigators' previous study first confirmed thalidomide treatment of GIVM bleeding was safe and effective. This prospective multi-center randomized controlled clinical trial intends to investigate the efficacy of thalidomide to the recurrent small intestinal hemorrhage due to GIVM.

Phase:

Phase 3

Details

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Collaborators:

Changhai Hospital
Huashan Hospital
Nanfang Hospital of Southern Medical University
Peking Union Medical College Hospital
Ruijin Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
The Second Hospital of Hebei Medical University
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Xinqiao Hospital of Chongqing

Treatments:

Thalidomide